RGC
Regencell Bioscience Holdings Limited
There isn't enough reported data to score RGC yet.
RGC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
RGC's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
RGC PE Valuation
RGC has no meaningful PE right now: it lost money over the past year.
RGC Forward outlook
There aren't enough analyst estimates for RGC to show an outlook.
RGC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2024 | -$0.01 | $0.00 |
| Q2 2023 | -$0.01 | +$0.01 |
| Q2 2022 | -$0.02 | -$0.02 |
RGC Quarterly Revenue
RGC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2025 | -$3.3M | +$740.8K |
| Q2 2024 | -$4M | +$983.3K |
| Q2 2023 | -$5M | +$1.1M |
RGC Net Leverage
RGC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RGC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 12.4 | Oversold |
RGC's weekly RSI is 36 (neutral) and its Stochastic is 12 (oversold).
RGC PE vs Healthcare Sector
RGC has no meaningful PE right now: it lost money over the past year.
RGC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.84 | 25% below |
| 20 week MA | $6.19 | 17% below |
| 50 week MA | $17.4 | 71% below |
| 100 week MA | $13.5 | 62% below |
| 200 week MA | $6.94 | 26% below |
RGC is in a downtrend: it's below all five of its weekly moving averages, and 26% below its 200-week average.
RGC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $0.28 | $0.69 | +146% |
| 2022 | $0.69 | $0.77 | +12% |
| 2023 | $0.77 | $0.28 | -64% |
| 2024 | $0.28 | $0.13 | -54% |
| 2025 | $0.13 | $21.2 | +16177% |
| 2026 YTD | $21.2 | $5.12 | -76% |
RGC's yearly returns have swung widely, from +16177% in 2025 to โ64% in 2023. It's down 76% so far in 2026.